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PreviewsAlthough their efforts to uncover Hnf1b
expression heterogeneity in the ductal
epithelium were unsuccessful, variability
cannot be definitively ruled out. The cells
that become marked could represent
a population of duct cells with a higher
activity of Hnf1b transcription or greater
accessibility to Cre recombinase.
Data supporting a duct origin for
islet cells postnatally in mice, rats, and
humans exist, but the ductal origin
hypothesis remains controversial and in
need of definitive experiments. Growth
of the exocrine pancreas from duct cells
during branching morphogenesis remains
an attractive hypothesis, which, surpris-
ingly, is unsupported by this paper. If
duct cells are not the origin of this
increase in b cell number after PDL,
what other candidates might produce so
many b cells this quickly? The demon-
strated increase in b cell replication after
PDL must account for some of the
increased b cell mass, with these repli-
cating cells being from either newly
formed or preexisting islets. If there are
nonduct precursor cells, they must exist
in reasonable numbers, but then why are
they not easier to identify?Assuming that the above caveats turn
out to be groundless, the studies by Ferrer
and colleagues considerably advance our
understanding of pancreas development.
Hnf1bCreER mice can be viewed as a
novel tool to identify components of
pancreas development. It can be con-
cluded that Hnf1b floxed duct cells do
not substantially contribute to endocrine
or acinar pancreas. In the future, we
imagine that Hnf1bCreER mice can be
applied to exclude pancreatic lineages
when searching for progenitors of b cell
expansion. Ultimately, it will be important
to confirm and expand the findings of
Ferrer and colleagues with lineage tracing
studies using additional markers that label
either ducts or other candidate precursor
cells.
In the end, the experiments by Ferrer
and colleagues challenge the duct origin
hypothesis, but the above caveats must
be addressed. If future similarly rigorous
experiments succeed in disproving the
duct cell origin, where do we look next
to explain the impressive regenerative
potential of the b cells? We anticipate
that the next few years will have many
surprises in this exciting field.Cell MetabolismREFERENCES
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Various members of the G protein-coupled receptor (GPCR) superfamily are known to modulate the release
of insulin from pancreatic b cells. Rosengren and colleagues have recently provided convincing evidence for
a role of increased expression of the a2A-adrenoceptor in b cells in the pathogenesis of type 2 diabetes.Type 2 diabetes (T2D) represents one of
the major threats to human health in the
21st century. One key feature of T2D is
that glucose fails to stimulate adequate
release of insulin from pancreatic b cells
to maintain normal blood glucose levels.For this reason, therapies targeted at
improving b cell function are predicted to
be of considerable therapeutic benefit.
The activity of pancreatic b cells is
modulated by several neurotransmitters
released from peripheral autonomicnerves (Ahre´n, 2000; Gilon and Henquin,
2001). The major neurotransmitter of
the peripheral parasympathetic nervous
system, acetylcholine, facilitates insulin
secretion from pancreatic b cells via
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Figure 1. Overexpression of the a2A Adrenoceptor in Pancreatic b Cells Results in Impaired Insulin Release
The a2A-adrenoceptor subtype is expressed on the surface of pancreatic b cells. Norepinephrine-mediated activation of the a2A adrenoceptor leads to the acti-
vation of G proteins of the Gi family, ultimately triggering reduced insulin release. Increased expression of the a2A adrenoceptor in b cells of rats or humans causes
impairments in insulin granule docking to the plasmamembrane and exocytosis. These latter deficits are due, at least in part, to increased activation of the protein
phosphatase, calcineurin (see text for details). AC, adenylyl cyclase; PKA, protein kinase A.
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Previewssubtype (Gilon and Henquin, 2001; Gau-
tam et al., 2006).
The endocrine pancreas is also richly
innervated by sympathetic nerves (Ahre´n,
2000). Electrical stimulation of these
nerves or norepinephrine administration
results in a pronounced inhibition in insulin
release (Ahre´n, 2000). Various lines of
evidence suggest that this effect is
mediated by activation of postsynaptic
a2-adrenoceptors expressed by pancre-
atic b cells (Ahre´n, 2000). Molecular
cloning studies have revealed the exis-
tence of three molecularly distinct
a2-adrenoceptor subtypes (a2A, a2B, and
a2C). The a2-adrenoceptors are prototypic
members of the GPCR superfamily and
exert most of their physiologic actions
via coupling to G proteins of the Gi family
(Philipp and Hein, 2004) (Figure 1). Accu-
mulating evidence suggests that b cell
a2A adrenoceptors play a central role in
mediating inhibition of insulin release
following treatment with a2-adrenoceptor
agonists or stimulation of sympathetic4 Cell Metabolism 11, January 6, 2010 ª2010pancreatic nerves (Devedjian et al., 2000;
Peterhoff et al., 2003).
Despite the known inhibitory role of a2A
adrenoceptors in mediating inhibition of
insulin release from pancreatic b cells,
the role of this receptor subtype in the
pathogenesis of T2D was unclear. Rose-
ngren et al. (2009) now provide strong
evidence that the a2A-adrenoceptor
subtype plays an important role in the
pathophysiology of T2D. Initially, the
authors analyzed congenic strains from
the Goto-Kakizaki (GK) rat, a widely
used model for T2D exhibiting insulin
resistance, impaired insulin secretion, as
well as various late complications associ-
ated with T2D. Rosengren et al. (2009)
convincingly demonstrated that a 1.4 Mb
genomic locus of the GK rat is linked to
reduced insulin release, due to impair-
ments in insulin granule docking at the
plasma membrane and granule exocy-
tosis. This 1.4 Mb GK-derived genetic
segment contains five known protein-
coding genes Whereas expression ofElsevier Inc.four of these genes was unchanged in
pancreatic islets from congenic rats con-
taining the 1.4 Mb GK-derived sequence
(N115 rats), interestingly the expression
of the fifth gene, Adra2a, encoding
the a2A adrenoceptor was found to be
significantly upregulated in these islets,
both at the mRNA and protein level.
Consistent with the in vitro studies,
in vivo experiments demonstrated that
N115 rats showed impaired glucose
tolerance, associated with a pronounced
reduction in glucose-stimulated insulin
release (GSIS).
Incubation of N115 islets with the
a2-adrenoceptor antagonist yohimbine
greatly enhanced GSIS. Moreover, treat-
ment of N115 islets with Adra2a siRNA
increased GSIS to levels similar to those
seen with control islets. Taken together,
these observations strongly support the
concept that the impaired insulin secre-
tion observed with N115 islets is caused
by overexpression of the a2A-adrenocep-
tor subtype. Additional in vitro studies
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Previewsshowed that the ability of b cell a2A adre-
noceptors to inhibit insulin release results
from the activation of pertussis toxin-
sensitive G proteins (G proteins of the
Gi family), and that overexpression of
a2A adrenoceptors leads to increased
activation of the protein phosphatase,
calcineurin, which interferes with insulin
granule recruitment.
On the basis of these findings, SNP
analysis of the human ADRA2A gene
was undertaken, and demonstrated a
linkage between the minor allele (A) of
rs553668, located in the 30 UTR region of
ADRA2A, and impaired insulin secretion
in humans. This SNP was associated
with reduced fasting insulin levels, and
reduced insulin secretion following oral
glucose administration. In addition, stu-
dies with a large cohort of nondiabetic
and diabetic individuals indicated that
ADRA2A rs553668 was associated with
increased risk of T2D.
Importantly, Rosengren et al. (2009)
went on to demonstrate that pancreatic
islets from risk A-allele carriers for
rs553668 overexpressed the a2A-adreno-
ceptor subtype, both at the mRNA and
protein level. Moreover, pancreatic islets
from risk carriers showed reduced basal
insulin secretion and a pronounced
reduction in GSIS, probably due to
a decrease in the number of docked
insulin granules. In agreement with the
results obtained with congenic rats (see
above), these impairments in insulin
secretion and insulin granule distribution
could be rescued by treatment with the
a2-adrenoceptor antagonist, yohimbine.
Taken together, these findings strongly
suggest that impaired insulin secretion
in rs553668 risk carriers results fromenhanced signaling through b cell a2A
adrenoceptors, suggesting the possibility
of tailoring specific treatments to indi-
vidual T2D patients.
As the a2A adrenoceptor is expressed in
many peripheral and central tissues, it is
not surprising that this receptor subtype
modulates many diverse physiological
functions, including regulation of blood
pressure and various metabolic pro-
cesses (Philipp andHein, 2004). Enhanced
signaling through a2A-adrenoceptors may
therefore also contribute to other patho-
physiological conditions. The widespread
expression of the a2A-adrenoceptor, how-
ever, suggests that the use of a2A-adreno-
ceptor antagonists for the treatmentof T2D
is likely to be associated with significant
side effects. Clearly, targeting drugs more
specifically to b cell a2A adrenoceptors or
downstream signaling proteins remains
a major challenge for future research.
Besides the a2A adrenoceptor, pancre-
atic b cells express a multitude of other
GPCRs, many of which are known to
modulate insulin release (Regard et al.,
2007; Ahre´n, 2009). Since GPCRs are
mostly found on the cell surface, these
receptors could represent excellent drug
targets for small molecule ligands.
Receptors that are coupled to the activa-
tion of Gq- and Gs-type G proteins have
attracted considerable interest as poten-
tial drug targets, primarily due to their
ability to stimulate insulin release (Ahre´n,
2009; Guettier et al., 2009). For example,
the GLP-1 receptor is a Gs-coupled
receptor that is highly enriched in pancre-
atic islets (Regard et al., 2007), and drugs
that act as agonists at this receptor (e.g.,
exendin 4) or compounds that inhibit the
enzymatic breakdown of GLP-1 (dipep-Cell Metabolismtidyl peptidase 4 inhibitors) have recently
been approved for the treatment of T2D
(Ahre´n, 2009).
Given the findings by Rosengren et al.
(2009), it is likely that sequence variations
in other GPCRs may also contribute to
the pathogenesis of T2D. Clearly, this
subject provides fertile ground for future
research. Hopefully, these efforts will
lead to the development of novel, more
specific GPCR-based therapies for the
treatment of T2D.
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